EU AI Act Guide

EU AI Act for US AI startups

US AI startups should assess EU AI Act exposure before scaling into European markets. The first questions are whether the product touches EU users, what role the company performs, and whether high-risk or documentation signals appear.

Run the diagnostic first

Operational information, not legal advice.

Company exposure map

EU AI Act for US AI Startups

01

Business context

02

EU customers, users or output

03

AI product or workflow use

04

Exposure path

Strategic answer

US AI startups should check EU exposure before product scale.

A US AI startup can create EU AI Act exposure when it sells into Europe, serves EU users, supports EU customer workflows or embeds AI into products used in the EU. Early diagnosis helps founders avoid building governance work after enterprise pressure has already arrived.

Start with the EU AI Act Diagnostic, turn findings into an implementation plan, and see how the diagnostic works as a reference app on M13.

Exposure focus

What US AI startups should clarify

  • Whether the product is offered to EU customers or users.
  • Whether the startup acts as provider, deployer or integration layer.
  • Whether AI outputs affect people, decisions or sensitive workflows.
  • Which documentation and oversight evidence customers may expect.

First action

What to do first

  1. 01Map product features with EU-facing AI exposure.
  2. 02Separate market exposure from internal AI use.
  3. 03Run role and risk triage before enterprise sales motion.
  4. 04Prepare a lightweight readiness evidence set before scale.

This page provides operational information for AI governance readiness. It is not legal advice.